08 September 2026
08 September 2026
Osaka's labs keep producing Nobel-level science. Companies are the harder problem - and Osaka is only just starting to solve it.
The purchase adds an established hypertension brand to the company's cardiovascular range.
The EAHP and EFPIA want all individual doses to carry a barcode, an addition they say will further reduce medication errors.
This follows the establishment of an invasive mosquito population in a region of Cyprus.
Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators.
The laboratory is expected to open in 2027 and create new jobs in the region.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
